Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5
| Autor: | Elias Kiwan, John D. Shaughnessy, Klaus Hollmig, Yazan Alsayed, Mauricio Pineda-Roman, John Crowley, Jeffrey Haessler, Bart Barlogie, Elias Anaissie, Frits van Rhee, Monica Graziutti, Sarah Waheed |
|---|---|
| Rok vydání: | 2008 |
| Předmět: | |
| Zdroj: | Blood. 112:162-162 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v112.11.162.162 |
| Popis: | We have previously reported on the remarkable activity of the TT3 program that incorporated both bortezomib (V) and thalidomide (T) into the up-front management of 303 patients. TT3 consisted of 2 cycles each of induction prior to and of dose-reduced consolidation therapy with VTD-PACE (cisplatin, doxorubicin, cyclophosphamide, etoposide) after melphalan 200mg/m2 (M200)-based tandem transplants, followed by maintenance therapy for 3 years with VTD and, in later stages, VRD (substituting T for lenalidomide, R). Characteristics included a median age of 59yr (range, 33–75yr), B2M >=4mg/L in 37%, albumin Figure 1a: Superior CR duration with TT3 v TT2 in GEP-low-risk MM: Figure 1a:. Superior CR duration with TT3 v TT2 in GEP-low-risk MM: Figure 1b: Superior event-free survival with TT3 v TT2 in GEP-high-risk MM: Figure 1b:. Superior event-free survival with TT3 v TT2 in GEP-high-risk MM |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|